b. detecting the presence of human iNOS protein in said sample, said ~~particular~~ binding monoclonal antibody recognizing human iNOS protein.

83(currently amended): A binding assay method for analysis of a sample, comprising the steps of:

a. contacting the sample with a ~~particular~~ binding entity specifically reactive to human iNOS without crossreacting with human nNOS or human eNOS, said ~~particular~~ binding entity selected from the group consisting essentially of an oligonucleotide, a polymer mimicking an artificial antibody, and a phage displayed binding site; and

b. detecting the presence of human iNOS protein in said sample, said ~~particular~~ binding entity specifically recognizing human iNOS protein.

84(previously presented): The method of claim 82 in which said region of human iNOS protein is selected from the group consisting essentially of the sequences: NNNVEKAPCATSSPVTQD (SEQ ID NO 32), SPVTQDDLQYHNLSKQQN (SEQ ID NO 26), NNNVEKAPCATSSPVTQD plus SPVTQDDLQYHNLSKQQN (SEQ ID NO 29), PALVQGILERVVDGPTPH (SEQ ID NO 30), GIVPFRSFWQQRLHDSQH (SEQ ID NO 25), and RMTLVFGSRRPDEDHITQ (SEQ ID NO 31).

85(previously presented): The method of claim 83 in which said region of human iNOS protein is selected from the group consisting essentially of the sequences: NNNVEKAPCATSSPVTQD (SEQ ID NO 32), SPVTQDDLQYHNLSKQQN (SEQ ID NO 26) NNNVEKAPCATSSPVTQD plus SPVTQDDLQYHNLSKQQN (SEQ ID NO 29),

PALVQGILERVVDGPTPH (SEQ ID NO 30), GIVPFRSFWQQRLHDSQH (SEQ ID NO 25), and RMTLVFGSRRPDEDHITQ (SEQ ID NO 31).

86(previously presented): The method of claim 82 in which said immunoassay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

87(previously presented): The method of claim 82 in which said step of detecting the presence of human iNOS protein comprises a qualitative analysis.

88(previously presented): The method of claim 82 in which said step of detecting the presence of human iNOS comprises a quantitative analysis.

89(previously presented): The method of claim 83 in which said binding assay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

90(currently amended): The method of claim [[82]] 83 in which said step of detecting the presence of human iNOS protein comprises a qualitative analysis.

91(currently amended): The method of claim [[82]] 83 in which said step of detecting the presence of human iNOS comprises a quantitative analysis.

92 (previously presented): A binding assay method for a sample,

comprising the steps of:

a. contacting the sample with a specific binding entity reactive to a mimic of human iNOS protein without cross-reacting with human nNOS protein or human eNOS protein; and

b. detecting the presence of human iNOS protein in said sample, said specific binding entity recognizing mimics of human iNOS protein.

93(previously presented): The method of claim 92 in which said mimic of human iNOS protein is selected from the group consisting essentially of: peptides, recombinant peptides, fusion proteins, fusion peptides, phage displayed proteins, phage displayed peptides, peptide libraries, and peptide analogue libraries.

94(previously presented): The method of claim 92 in which said specific binding entity is selected from the group consisting essentially of:

a monoclonal antibody, an oligonucleotide, a polymer mimicking an artificial antibody, and a phage displayed binding site.

95(previously presented): The method of claim 89 in which said region of human iNOS protein is selected from the group consisting essentially of the sequences: NNNVEKAPCATSSPVTQD (SEQ ID NO 32), SPVTQDDLQYHNLSKQQN (SEQ ID NO 26), NNNVEKAPCATSSPVTQD plus SPVTQDDLQYHNLSKQQN (SEQ ID NO 29), PALVQGILERVVDGPTPH (SEQ ID NO 30), GIVPFRSFWQQRLHDSQH (SEQ ID NO 25), and RMTLVFGSRRPDEDHITQ (SEQ ID NO 31).

96(previously presented): The method of claim 92 in which said binding assay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

97(previously presented): The method of claim 92 in which said binding assay comprises a clinical diagnostic assay.

98(previously presented): The method of claim 92 in which said step of detecting the presence of human iNOS protein comprises a qualitative analysis.

99(previously presented): The method of claim 92 in which said step of detecting the presence of human iNOS comprises a quantitative analysis.

100(previously presented): The method of claim 92 in which said specific binding entity comprises any one of the peptide analogues of Table VII.

101(previously presented): The method of claim 92 in which said specific binding entity comprises any one of the peptide analogues of Table IX.

102(previously presented): The method of claim 92 which is of the type selected from the group consisting essentially of: IFA, linear flow, radial flow, Western Blot, ELISA, dip stick, EIA, fluorescent polarization, enzyme capture, and RIA.

103(previously presented): The method of claim 82 which is of the type selected from the group consisting essentially of: IFA, linear flow, radial flow, Western Blot, ELISA, dip stick, EIA, fluorescent polarization, enzyme capture, and RIA.

104(previously presented): The method of claim 100 in which said specific binding entity is a peptide analogue having

the sequence: VTQDDLQ (SEQ ID NO 89).

105(previously presented): The method of claim 101 in which said specific binding entity is a peptide analogue having the sequence: VQGILERV (SEQ ID NO 120).

106(cancelled): A binding assay for iNOS contained in a sample comprising:

a. a specific binding entity reactive to human iNOS; and

b. a vehicle for revealing the presence of human iNOS according to said specific binding entity recognizing a region of human iNOS protein.